Ketil Widerberg, general manager of Oslo Cancer Cluster, represented Norway in one of the panel sessions during Global Health Security Demo Day at SXSW2021.

Norwegian life science @ SXSW2021

We put global health security on the agenda at the influential technology conference SXSW.

Oslo Cancer Cluster and the other Norwegian health clusters Norway Health Tech and The Life Science Cluster participated in the conference South by South West (SXSW) for the first time ever last week.

The conference usually takes place in Austin (Texas), but due to current corona restrictions it was made available through an online platform.

The full-day event Global Security Demo Day, arranged by The Texas Global Health Security Innovation Consortium (TEXGHS), attracted many big names in health and life science from across the globe on Wednesday 17 March.

“It is clear that there is a silver lining of accelerated development, new innovations and increased public-private partnership in health emerging from the current Covid-crisis,” said Ketil Widerberg, general manager of Oslo Cancer Cluster.

The Norwegian life science environment was also represented at this event, by keynote speaker Bent Høie, Minister of Health and Care Services, several representatives from private companies and the heads of the Norwegian health clusters Oslo Cancer Cluster, Norway Health Tech and The Life Science Cluster.

“It is great that Bent Høie, the Norwegian Minister of Health, supports innovative health companies at one of the world’s largest technology conferences in Texas,” said Ketil Widerberg.

View the panel sessions

Watch the video above for the panel session The race to a vaccine with Ketil Widerberg, general manager of Oslo Cancer Cluster and Trent Munro, Professor at Australian Institute for Bio-Engineering and Nanotechnology, moderated by Janet Walkow Executive Director and CTO, Drug Dynamics Institute, UT Austin.

The event was organised by TEXGHS, Austin Technology Incubator at the University of Texas at Austin, Australian Trade and Investment Commission (Austrade), Consulate General of Denmark in Houston, The Royal Norwegian Consulate General in Houston and European Network of Research and Innovation Centres and Hubs, USA (ENRICH).

Oslo Cancer Cluster Incubator staff runs the programme OCC Accelerator to help companies in cancer innovation succeed. Photo: Christopher Olssøn/Oslo Cancer Cluster

OCC Accelerator is here

Oslo Cancer Cluster Incubator relaunches the programme for start-ups in cancer innovation under the new name OCC Accelerator.

OCC Accelerator will identify, select, and develop promising innovations that will improve the lives of cancer patients. The aim is to make the projects attractive for private and public investments.

“This programme is for the best research projects and start-ups with innovative technology in cancer and a strong commercial potential.”

“This programme is for the best research projects and start-ups with innovative technology in cancer and a strong commercial potential. It is publicly funded with the overarching goal to build Norwegian health industry,” said Bjørn Klem, general manager, Oslo Cancer Cluster Incubator.

OCC Accelerator is a programme led by Oslo Cancer Cluster Incubator and it is funded by Siva, a governmental enterprise facilitating a national infrastructure for innovation.

“2021 will be a challenging year because of the corona pandemic, but thanks to Siva we can offer up to 100% discounted services to the Accelerator companies,” said Bjørn Klem.

How does the programme work?

OCC Incubator regularly meet with researchers, founders, and entrepreneurs to discuss whether their ideas have commercial potential. After a comprehensive evaluation and approval from the board, the project or start-up may be admitted to the OCC Accelerator programme.

“We tailor our services according to each company’s needs.”

“We tailor our services according to each company’s needs. Some companies need help with a specific challenge, while others need support with everything during the start-up phase,” Bjørn Klem said.

The activities often include to establish the company, secure intellectual property rights, fund the company, set up development plans, and recruit management, advisors, consultants, and a board of directors.

Help with funding

For most companies the most important thing is to pursue equity investments and public funding. OCC Incubator helps the company navigate the complex landscape of funding grants, coach them before negotiations with potential investors and provide valuable contacts.

The global network through Oslo Cancer Cluster also gives the companies exposure through international partnering conferences, pitching events and official communication channels.

Moreover, the OCC Accelerator companies have access to the OCC Incubator’s state-of-the-art laboratories and offices in Oslo Cancer Cluster Innovation Park.

Oslo Cancer Cluster Incubator offers state-of-the-art laboratories for researchers in the cancer field. Photo: Christopher Olssøn

Oslo Cancer Cluster Incubator offers state-of-the-art laboratories for researchers in the cancer field. Photo: Christopher Olssøn

“We can work intensely with companies for periods of time, but eventually they need to stand on their own feet. Our main goal is to make them attractive for investments,” Bjørn Klem said.

The companies may stay up to 4 years in the programme. Their progress is evaluated on a yearly basis to ensure they reach the necessary milestones.

One success story

Kongsberg Beam Technology is one of the companies currently in the OCC Accelerator programme. The company has benefited in several ways. Bjørn Klem has helped the founders write funding applications and arranged investor meetings. Thomas Andersson, Senior Advisor for Business Development in Oslo Cancer Cluster Incubator, aided in recruiting the CEO Kerstin Jakobsson to the company and retains a seat on the board.

After the company’s first investor presentation in February 2021, the first issue of shares was oversubscribed in less than two days to the amount of 13MNOK. The company is also supported by the Norwegian Research Council with 23MNOK.

“We would not be where we are today without the support of Oslo Cancer Cluster Incubator.”

“Kongsberg Beam Technology is a medtech company in oncology. It is very important for us as a start-up company to be part of a life science community such as Oslo Cancer Cluster Incubator and have access to their network and partner meetings. We would not be where we are today without the support of Oslo Cancer Cluster Incubator. They have helped us with important funding contacts, to prepare the crucial investor meetings, which have secured our initial funding,” said Kerstin Jakobsson, CEO of Kongsberg Beam Technology.


If you are a researcher, founder or entrepreneur with an idea in cancer innovation with commercial potential, you are welcome to apply to OCC Accelerator. Please contact Bjørn Klem to find out more.


 

Cancer researchers Åslaug Helland, Simone Mester, Sigrid Skånland and Else Marit Inderberg talk about equality on International Women's Day.

Talking about cancer research and equality

International Women’s Day: three Norwegian researchers share their personal stories of being women in the cancer field.

Every year, International Women’s Day is marked on the 8th of March to put gender equality on the agenda. We wish to use this opportunity to celebrate women dedicated to developing new cancer treatments. It is important for us to highlight researchers that perform important research, who can also be role models.

We have reached out to cancer researchers across Norway, both in the public and the private sector. As a result, three accomplished Norwegian researchers share their personal perspectives. They are at different stages in their careers and focusing on different areas of research.

 


Åslaug Helland. Photo: Oslo University Hospital

Åslaug Helland. Photo: Oslo University Hospital

Combining family life and research

Åslaug Helland is a Group leader at the Institute for Cancer Research at the Norwegian Radium Hospital in Oslo and Senior Oncologist at the Department of Oncology at Oslo University Hospital. Helland’s research group focuses on translational studies on solid tumours, with a special interest in pancreatic cancers, lung cancers, ovary cancers and colorectal cancers.

“First of all, being involved in cancer research has been extremely rewarding. I started when still at med-school, in 1991, and since then we have learned a lot. Today we see that the insights gained some years ago benefit patients!

“When I started working in cancer research, there was a male dominance, which is not as obvious today. I started in Anne-Lise Børresen-Dale’s group at the Norwegian Radium Hospital. She was a world leading researcher in cancer molecular genetics and working with her was very inspiring.

“The regulations in Norway have made it possible for both men and women to combine family life and research.

“My family and I have lived abroad twice for research stays, first at Stanford University and thereafter at Peter MacCallum Cancer Centre in Melbourne, Australia, and my experience is that Norway is one of the most advanced countries in gender balance and equal opportunities.”

 


 

Sigrid Skånland. Photo: Private.

Sigrid Skånland. Photo: Private.

Let me hold the door for you

Sigrid S. Skånland is a PhD, Project group leader, lab leader and researcher at the Institute for Cancer Research at Oslo University Hospital. Skånland has established her own research group, focusing on functional precision medicine in haematological cancers, in particular the B-cell malignancy chronic lymphocytic leukemia.

“When I talk about gender equality, I do it for my daughters. Their future. When they show bold confidence, I think ‘You go, girl!’

I want them to feel that they can claim their space, even as girls. I want them to see that it is possible to be smart, strong and successful, even as a single mom. I want them to be valued equally to men, also when they become women.

“As a biologist, most of my fellow students were female, and most of my colleagues during my graduate and post-graduate studies were women. As I have become more senior, my perspective has changed. Most students and trainees are still women. But. When I go to conferences, I see that most of the speakers are men. When I apply for research funding, I see that most of the grants are awarded to men. And when I establish new collaborations, I see that most of the higher positions are filled by men. I want everyone to see this.

“My daughter sat with me through a virtual conference. She pointed to the screen and said: ‘Are there only men?’ At the age of five, she already sees it.

“As a woman, I need women in leading positions to look up to. And I greatly appreciate the men who also see the value of acknowledging and promoting excellent female scientists. After 40 years, the first female members were elected to the international workshop on chronic lymphocytic leukaemia in 2019. This could not have happened without the support from the men on the board. Together, we can raise awareness on gender equality and make the gender gap smaller.

“I hope that I can inspire other women. Kamala Harris said it nicely: ‘It’s on those of us leading the way to leave the door more open than it was when we walked in.’”

 


 

Simone Mester. Photo: University of Oslo

Simone Mester. Photo: University of Oslo

Follow your dreams!

Simone Mester is a PhD student at The Laboratory of Adaptive Immunity and Homeostasis, which is part of both the Medical Faculty at the University of Oslo and Department for Immunology and Transfusion Medicine at Oslo University Hospital. Her research focus is on development of new biomedical technologies that may make cancer treatments more precise and effective. Her ambition is to start a biotechnology company in Norway.

Mester attended Ullern Upper Secondary School, which has an active collaboration with Oslo Cancer Cluster to inspire students to pursue careers in science and entrepreneurship. She was also the youngest researcher to be selected to SPARK, the University of Oslo’s two-year innovation programme. When she won the SPARK “pitch challenge”, she was awarded a six-month stay in ShareLab, where she now is exploring the commercial potential of her research results together with her colleague Torleif Tollefsrud Gjølberg, also a PhD student in the same laboratory.

“Early in my career, I have experienced great opportunities and lot of support. I strongly feel that the life science ecosystem is supporting me and would like to see me succeed. This is very motivating!

“For me, it is important to be part of a dynamic research environment that allows me to explore and develop as a researcher.

“I would like to encourage students and young researchers to be brave, ambitious and to follow their dreams!”

 


Else Marit Inderberg. Photo: Oslo University Hospital

Else Marit Inderberg. Photo: Oslo University Hospital

Calling for clear career paths

Else-Marit Inderberg is a Senior Researcher and Group leader at the Department of Cellular Therapy at Oslo University Hospital-The Norwegian Radium Hospital. The focus of her research is immunomonitoring in clinical studies and the development of cell therapies in cancer treatments. Inderberg’s research group uses the offices and facilities in Oslo Cancer Cluster Incubator.

“My experience as a woman in cancer research in Norway is very good and my supervisors and mentors were always very supportive.

“I was always given opportunities to take on responsibility and to be independent and it was up to me to decide if I wanted or could grab them or not.

One of the key things to change to keep future generations motivated to do cancer research is to have clear career paths for researchers, both female and male.

 


 

Kerstin Jakobsson, CEO, Kongsberg Beam Technology.

Experienced CEO joins Kongsberg Beam Technology

Kerstin Jakobsson, CEO of Kongsberg Beam Technology

Kerstin Jakobsson has been appointed CEO to our member the Norwegian medtech company Kongsberg Beam Technology.

Kongsberg Beam Technology develops an advanced steering system able to deliver personalised proton therapy with better precision and less damage to healthy tissue. Proton therapy is an accepted and established cancer treatment and compared to traditional radiation therapy it focuses the energy on the tumour itself with less radiation to surrounding healthy tissue.

Kerstin Jakobsson has over thirty years of experience in the commercialisation of new technologies in the life science sector, with responsibility for international strategic and operational leadership. Jakobsson has been part of the management team of Medicon Village since the start and CEO for the last three years and has developed it into one of Scandinavia’s leading life science innovation parks.

Oslo Cancer Cluster Incubator has worked closely with Kongsberg Beam Technology for several years to develop the company through its SIVA-sponsored programme. Bjørn Klem, general manager, and Thomas Andersson, senior advisor business development, have taken a hands-on approach, which is what attracted Jakobsson to the position as CEO.

“I am familiar with Oslo Cancer Cluster because the organisation covers areas of interest with Medicon Village. I have known Bjørn for many years through the NOME network and Thomas introduced Kongsberg Beam Technology to me,” Jakobsson explained.

Jakobsson has worked with many different start-ups and public listed companies throughout the years. For instance, Jakobsson was CEO for the two successful medtech companies Spectracure and Ortoma – both are now listed on the Swedish stock exchange.

“I am an entrepreneur at heart, and I feel at home in start-ups.”

“I am an entrepreneur at heart, and I feel at home in start-ups. I prefer a good mix of strategy and implementation, which is possible in smaller organisations. To build and develop a company is very rewarding. I am also familiar with the challenges in taking on this role. I benefit from my contacts in the extensive life science network that I have built over the years,” Jakobsson commented.

Focus on personalised healthcare

Kongsberg Beam Technology is a company focused on improving proton therapy in oncology. There are 20 million cancer cases every year and many cancer patients benefit from radiation therapy. The disadvantage is that radiation therapy has several side effects on healthy tissue. Proton therapy allows more control as to exactly where the energy from the particles is released, without damaging healthy tissue surrounding the tumour.

“With proton therapy, the dosage is delivered to a more specific target, the tumour. The dosage is considerably less in the surrounding healthy areas, which can make a noticeable difference for the occurrence of side effects,” said Jakobsson.

“Using artificial intelligence and digital twins, it will be possible to control the proton beam in real-time during treatment.”

Kongsberg Beam Technology develops a steering system called MAMA-K that will make proton therapy even more personalised and precise, and with MAMA-K the full potential of proton therapy can be achieved. Using artificial intelligence and digital twins, it will be possible to control the proton beam in real-time during treatment, even when the patients or their organs are inadvertently moving.

“Kongsberg Beam Technology is an interesting company, because the technology is highly advanced, and the management are extremely skilled and experienced. There is a solid market need, with a large potential for growth, and there is a long-term vision connected to the construction of two new proton therapy facilities in Norway,” Jakobsson explained.

The future for proton therapy

Proton therapy is emerging as a critical treatment method against cancer, which is why Norway are building two proton centres. The centres are planned to be completed in 2024 and are located at the Radium Hospital in Oslo and Haukeland University Hospital in Bergen. Kongsberg Beam Technology already has a collaboration agreement with the Radium Hospital, which is a part of Oslo University Hospital (a comprehensive cancer centre), to use the prospective facilities to test the MAMA-K system.

“The unique thing about Kongsberg Beam Technology is the strong collaboration between the Kongsberg industry, Oslo Cancer Cluster, Oslo University Hospital and the university.”

“The unique thing about Kongsberg Beam Technology is the strong collaboration between the Kongsberg industry, Oslo Cancer Cluster, Oslo University Hospital and the university. Spearhead knowledge from the Kongsberg industry is the basis for the technology. Oslo Cancer Cluster has provided a network in oncology which has made it possible to take the patented ideas further. We are essentially identifying the bottle necks in proton therapy to deliver solutions for the treatment centres,” said Jakobsson.

The plan for 2021 was to attract NOK 10 million in private placements. Less than two days after the first investor presentation, the emission was oversubscribed to NOK 13 million. Now, the company’s focus is to deliver a proof of concept within the next 12 months. The Norwegian Research Council is already supporting the company during this development phase with NOK 23 million.

Do you want to learn more?

Get in touch with Kerstin Jakobsson at kerstin.jakobsson@kongsbergbeamtech.com

Listen to Jakobsson’s guest appearance in the Radium podcast: Episode 161 by Radforsk Investeringsstiftelse (in Norwegian/Swedish only)

Read about Kongsberg Beam Technology in the following news articles: (in Norwegian only)

Previous articles on oslocancercluster.no about Kongsberg Beam Technology: